Abstract 344TiP
Background
A Phase 3 CAPSTONE-1 clinical trial demonstrated the effectiveness and safety of adebrelimab plus chemotherapy as the first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). The phase III ETER701 clinical trial demonstrated the survival benefits of adding anlotinib to benmelstobart and chemotherapy, but the risks of hemoptysis and occult blood test positive cannot be ignored. Apatinib, used as maintenance therapy following standard first‐line chemotherapy in ES-SCLC, showed promising efficacy and acceptable safety in a phase II clinical trial (NCT03129698). Currently, there is no clinical study on adebrelimab plus apatinib for maintenance treatment of ESSCLC after first-line induction with adebrelimab plus chemotherapy.
Trial design
This is a multicenter, single-arm, phase II clinical trial. The key inclusion criteria are 1) age 18 years and above, 2) diagnosis of ESSCLC confirmed by histology or pathology, 3) Eastern Cooperative Oncology Group Performance Status 0–2, and 4) systematic treatment for ES-SCLC naïve. The primary endpoint is progression-free survival (PFS). The secondary endpoints include objective response rate, disease control rate, PFS2, duration of response, overall survival, and safety.
Clinical trial identification
NCT06480864.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.